Taro Semba

1.3k total citations
28 papers, 594 citations indexed

About

Taro Semba is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Taro Semba has authored 28 papers receiving a total of 594 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Taro Semba's work include Cancer Treatment and Pharmacology (7 papers), Glycosylation and Glycoproteins Research (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Taro Semba is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Glycosylation and Glycoproteins Research (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Taro Semba collaborates with scholars based in Japan, United States and Netherlands. Taro Semba's co-authors include Yasuhiro Funahashi, Toshiaki WAKABAYASHI, Yoichi Ozawa, Kentaro Yoshimatsu, Yusuke Adachi, Junji Matsui, Satoshi Kawano, Yuji Yamamoto, Naoko Hata Sugi and Osamu Tohyama and has published in prestigious journals such as Journal of Biological Chemistry, Cancer and Cancer Research.

In The Last Decade

Taro Semba

28 papers receiving 573 citations

Peers

Countries citing papers authored by Taro Semba

Since Specialization

Citations

This map shows the geographic impact of Taro Semba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taro Semba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taro Semba more than expected).

Fields of papers citing papers by Taro Semba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taro Semba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taro Semba. The network helps show where Taro Semba may publish in the future.

Co-authorship network of co-authors of Taro Semba

This figure shows the co-authorship network connecting the top 25 collaborators of Taro Semba. A scholar is included among the top collaborators of Taro Semba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taro Semba. Taro Semba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort 2024 ·Cancer Research Communications ·Makoto Nishio, Shuji Murakami, Hisato Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, (unknown), (unknown), (unknown), (unknown), Taro Semba, Koichi Azuma	2
2	Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort 2024 ·Clinical Cancer Research ·Akihito Kawazoe, Noboru Yamamoto, (unknown), Hisato Kawakami, Takashi Oshima, Kensei Yamaguchi, (unknown), Motohiro Hirao, Yukinori Kurokawa, Takeshi Kawakami, Masahiro Tsuda, Hiroki Hara, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Taro Semba, Kei Muro	3
3	Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities 2023 ·Molecular Cancer Therapeutics ·Ken Ito, Masayuki Yamaguchi, Taro Semba, Kimiyo Tabata, (unknown), Muneo Aoyama, Takanori Abe, Osamu Asano, Yasuhiko Terada, Yasuhiro Funahashi, Hirofumi Fujii	1
4	Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody 2023 ·Molecular Cancer Therapeutics ·Yuki Niwa, (unknown), Kimiyo Tabata, (unknown), (unknown), (unknown), Yuji Mano, Yoichi Ozawa, Yukinori Minoshima, Yasuhiro Funahashi, Taro Semba	8
5	First‐in‐human study of E7130 (a tumor microenvironment‐ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose‐escalation part 2023 ·Cancer ·Toshihiko Doi, Nobuaki Matsubara, Yoichi Naito, Yasutoshi Kuboki, Kenichi Harano, Makiko Ono, Tetsuya Urasaki, Akihiro Ohmoto, (unknown), Takashi Hisai, Hiroki Ikezawa, (unknown), Ken Ito, Taro Semba, Osamu Asano, Shunji Takahashi	3
6	405P E7389-LF as a first-line (1L) chemotherapy for patients (pts) with metastatic/advanced HER2-negative breast cancer (HER2− BC): Results from a phase I study dose-expansion part 2023 ·Annals of Oncology ·(unknown), Yukiko Miyoshi, Hiroyuki Yasojima, Junichiro Watanabe, Toshimi Takano, Akihiko Shimomura, Eriko Tokunaga, Toru Mukohara, Yasuto Naoi, Satoshi Okumura, Takuya Suzuki, (unknown), Daisuke Matsuoka, (unknown), Taro Semba, Hiroshi Ishiguro	1
7	Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort 2023 ·Clinical Cancer Research ·Kohei Shitara, Motohiro Hirao, Satoru Iwasa, Takashi Oshima, Yoshito Komatsu, Akihito Kawazoe, Yasuyoshi Sato, Takuya Hamakawa, Kan Yonemori, Nozomu Machida, Satoshi Yuki, Takuya Suzuki, (unknown), (unknown), Taro Semba, Bob Zimmermann, (unknown), Kensei Yamaguchi	3
8	Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort 2022 ·European Journal of Cancer ·Norikazu Masuda, Makiko Ono, Toru Mukohara, Hiroyuki Yasojima, Tatsunori Shimoi, Kokoro Kobayashi, Kenichi Harano, Makiko Mizutani, Maki Tanioka, Shunji Takahashi, Takahiro Kogawa, Takuya Suzuki, (unknown), (unknown), (unknown), Taro Semba, Zi-Ming Zhao, Min Ren, Kan Yonemori	5
9	New Cluster Analysis Method for Quantitative Dynamic Contrast‐Enhanced MRI Assessing Tumor Heterogeneity Induced by a Tumor‐Microenvironmental Ameliorator (E7130) Treatment to a Breast Cancer Mouse Model 2022 ·Journal of Magnetic Resonance Imaging ·(unknown), Masayuki Yamaguchi, Ken Ito, (unknown), Yusaku Hori, Taro Semba, Yasuhiro Funahashi, Hirofumi Fujii, Yasuhiko Terada	2
10	Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models 2020 ·Anticancer Research ·Yuki Niwa, Makoto Asano, Takayuki Nakagawa, (unknown), Taro Semba, Yasuhiro Funahashi	2
11	Clinical benefit of eribulin (Halaven<sup>®</sup>) in the treatment of advanced soft tissue sarcoma patients and the novel anti-tumor mechanisms 2016 ·Folia Pharmacologica Japonica ·Noriyuki Koyama, (unknown), Kotaro Kodama, Osamu Tohyama, Hiroki Hasegawa, Taro Semba	1
12	Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models 2014 ·Cancer Science ·Yasuhiro Funahashi, Kiyoshi Okamoto, Yusuke Adachi, Taro Semba, Mai Uesugi, Yoichi Ozawa, Osamu Tohyama, Taisuke Uehara, Takayuki Kimura, Hideki Watanabe, Makoto Asano, Satoshi Kawano, Xavier Tizon, Paul J. McCracken, Junji Matsui, Ken Aoshima, K. Nomoto, Yoshiya Oda	212
13	Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway‐induced resistance to vascular endothelial growth factor receptor inhibitor 2014 ·Cancer Science ·Takayuki Nakagawa, Tomohiro Matsushima, Satoshi Kawano, Youya Nakazawa, Yu Kato, Yusuke Adachi, Takanori Abe, Taro Semba, Akira Yokoi, Junji Matsui, Akihiko Tsuruoka, Yasuhiro Funahashi	32
14	Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies 2011 ·The AAPS Journal ·Ron J. Keizer, Yasuhiro Funahashi, Taro Semba, J. Wanders, Jos H. Beijnen, Jan H.M. Schellens, A. D. R. Huitema	19
15	An Angiogenesis Inhibitor E7820 Shows Broad-Spectrum Tumor Growth Inhibition in a Xenograft Model 2004 ·Clinical Cancer Research ·Taro Semba, Yasuhiro Funahashi, (unknown), Yuji Yamamoto, Naoko Hata Sugi, Makoto Asada, Kentaro Yoshimatsu, Toshiaki WAKABAYASHI	62
16	Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. 2002 ·PubMed ·Yasuhiro Funahashi, Naoko Hata Sugi, Taro Semba, Yuji Yamamoto, (unknown), (unknown), Yoichi Ozawa, Akihiko Tsuruoka, (unknown), Keiko Takahashi, Tadashi Okabe, Junichi Kamata, Takashi Owa, Norihiro Ueda, Toru Haneda, Masahiro Yonaga, Kentaro Yoshimatsu, Toshiaki WAKABAYASHI	94
17	Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor. 1999 ·PubMed ·Yasuhiro Funahashi, Toshiaki WAKABAYASHI, Taro Semba, Jiro Sonoda, Kyosuke Kitoh, Kentaro Yoshimatsu	37
18	Studies on Thermophile Products. IX. Isofatty Acid-Containing Phosphatidylglycerol That Enhances the Induction of Concanavalin A-Activated Suppressor T Cells. 1994 ·Biological and Pharmaceutical Bulletin ·Yasuhiro Kohama, Taro Semba, Kuniaki Tanaka, (unknown), Shigeyasu Tanaka, Susumu Itoh, Toshihide Mimura	1
19	Studies on Thermophile Products. VI. Activation of Mouse Peritoneal Macrophages by Bis(2-hydroxyethyl) Trisulfide. 1993 ·Biological and Pharmaceutical Bulletin ·(unknown), K. Iida, (unknown), Taro Semba, Masahiko Itoh, Takashi Teramoto, Kazutake Tsujikawa, TSUTOMU MIMURA	4
20	Studies on Thermophile Products. IV. Structural Elucidation of Cytotoxic Substance, BS-1, Derived from Bacillus stearothermophilus. 1992 ·Chemical and Pharmaceutical Bulletin ·Yasuhiro Kohama, K. Iida, Taro Semba, Toshihide Mimura, Akari Inada, (unknown), Takashi Nakanishi	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact